Search

A vaccine is likely the most effective strategy for controlling human chlamydial infections. Recent studies have shown immunization with Chlamydia muridarum major outer membrane protein (MOMP) can induce significant protection against infection and disease in mice if its native trimeric structure is preserved (nMOMP). The objective of this study was to investigate the immunogenicity and vaccine efficacy of Chlamydia trachomatis nMOMP in a nonhuman primate trachoma model. Cynomolgus monkeys (Macaca fascicularis) were immunized systemically with nMOMP, and monkeys were challenged ocularly. Immunization induced high serum IgG and IgA ELISA Ab titers, with Abs displaying high strain-specific neutralizing activity. The PBMCs of immunized monkeys produced a broadly cross-reactive, Ag-specific IFN-γ response equivalent to that induced by experimental infection. Immunized monkeys exhibited a significant decrease in infectious burden during the early peak shedding periods (days 3–14). However, at later time points, they exhibited no difference from control animals in either burden or duration of infection. Immunization had no effect on the progression of ocular disease. These results show that systemically administered nMOMP is highly immunogenic in nonhuman primates and elicits partially protective immunity against ocular chlamydial challenge. This is the first time a subunit vaccine has shown a significant reduction in ocular shedding in nonhuman primates. A partially protective vaccine, particularly one that reduces infectious burden after primary infection of children, could interrupt the natural trachoma reinfection cycle. This would have a beneficial effect on the transmission between children and sensitized adults which drives blinding inflammatory disease.

Trachoma, caused by Chlamydia trachomatis, is the world’s leading cause of preventable blindness for which a vaccine is needed. We previously described a live-attenuated trachoma vaccine (LATV) in non-human primates (Kari L. 2011 JEM 208: 2217-23). Vaccinated macaques were either solidly or partially protected following challenge with virulent trachoma organisms. Our current goal was to characterize immune responses that correlated with solid protective immunity. Here, we preformed intramuscular boosting of LATV vaccinated macaques and studied the T cell recall response in PBMC by flow cytometry. Both solidly and partially protected macaques exhibited a strong PBMC CD8+ T recall response following intramuscular immunization. Notably, however; only CD8+ T cells from solidly protected macaques strongly proliferated in response to chlamydial soluble antigen (SA) prepared from chlamydial infected cells. The SA contained proteins known to be secreted by chlamydiae into the host cytosol making them logical antigenic targets of cytotoxic CD8+ T cells. The SA expanded CD8+ T cells expressed IFN-γ, granzyme B, and α4β7 integrin implicating them as effectors important to the development of solid protective immunity at the ocular mucosae. Identifying the effector function and antigens recognized by these CD8+ T cells will be the focus of future studies as this information will provide insights into the design of more conventional immunotherapeutic approaches for trachoma control.